FRANKLIN, Mass., Oct. 2 /PRNewswire-FirstCall/ -- Echo Therapeutics,
Inc. (OTC Bulletin Board: ECTE) announced today that Patrick T. Mooney,
M.D., Chairman and Chief Executive Officer, will present at the JMP
Securities Healthcare Investor Conference on October 7, 2008 at 10:00 am
Eastern Standard Time. The presentation will occur live and will be held at
Le Parker Meridien Hotel in New York City.
About Echo Therapeutics
Echo Therapeutics is focused on transdermal medical devices and
specialty pharmaceuticals. Echo's Symphony(TM) tCGM System is in late-stage
development as a non-invasive (needle-free), wireless, transdermal
continuous glucose monitoring (tCGM) system for patients with Type 1 and
Type 2 diabetes and for use in hospital critical care units. Echo's AzoneTS
reformulation technology is focused on building a pipeline of safer and
improved versions of widely- prescribed, FDA-approved specialty
pharmaceutical products. Echo's Symphony tCGM System consists of its
wireless transmission and transdermal biosensor technologies and its
Prelude(TM) SkinPrep System, which incorporates leading- edge, needle-free
skin permeation control. Echo expects the Symphony tCGM System to provide
both diabetics and hospital professionals with a reliable, affordable,
comfortable-to-wear, and easy-to-use, needle-free continuous glucose
monitoring device.
Forward-Looking Statements
This press release contains forward-looking information that involves
risks and uncertainties, including statements regarding Echo's development
plans, objectives, expectations and intentions, including, without
limitation, statements regarding the Company's Symphony tCGM System and
AzoneTS product candidates. Factors that could adversely affect Echo's
business and prospects are described in the Company's filings with the
Securities and Exchange Commission. Echo expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any such
statements to reflect any change in the Company's expectations or any
change in events, conditions or circumstances on which any such statement
is based.
Investor Relations Contacts:
Patrick T. Mooney, M.D.
Chairman & CEO
Echo Therapeutics
508-530-0329
Lilian Stern
Stern Investor Relations
212-362-1200
SOURCE Echo Therapeutics, Inc.
 back to top
Related links:
http://www.echotx.com
CONTACT:
Investors, Patrick T. Mooney, M.D., Chairman
& CEO of Echo Therapeutics, +1-508-530-0329, or Lilian Stern of
Stern Investor Relations, +1-212-362-1200
|
